UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 135

Sortiert nach

CRR visuell: Die neuen EU-Vorschriften der Capital Requirements Regulation

3, 2020

Link zum Volltext

Verfügbarkeit prüfen

ZAG: Kommentar zum Zahlungsdiensteaufsichtsgesetz

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-12, Vol.29 (34), p.4574-4580

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2017-10, Vol.35 (30), p.3449-3457

2017

Link zum Volltext

Verfügbarkeit prüfen

Experience With Afatinib in Patients With Non‐Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib

The oncologist (Dayton, Ohio), 2014-10, Vol.19 (10), p.1100-1109

2014

Link zum Volltext

Verfügbarkeit prüfen

Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology

Annals of nuclear medicine, 2012-05, Vol.26 (4), p.365-369

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Ixabepilone or Paclitaxel Plus Carboplatin in Patients With Non–Small-Cell Lung Cancer Prospectively Stratified by Beta-3 Tubulin Status

Journal of clinical oncology, 2013-06, Vol.31 (16), p.1990-1996

2013

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)

Journal of thoracic oncology, 2012-01, Vol.7 (1), p.203-211

2012

Link zum Volltext

Verfügbarkeit prüfen

Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer

Oncotarget, 2017-11, Vol.8 (57), p.97061-97078

2017

Link zum Volltext

Verfügbarkeit prüfen

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study

Journal of thoracic oncology, 2008-12, Vol.3 (12), p.1446-1453

2008

Link zum Volltext

Verfügbarkeit prüfen

Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study

Journal of thoracic oncology, 2014-08, Vol.9 (8), p.1154-1161

2014

Link zum Volltext

Verfügbarkeit prüfen

Standardized quantification of circulating peripheral tumor cells from lung and breast cancer

Clinical chemistry and laboratory medicine, 2005-01, Vol.43 (6), p.617-627

2005

Link zum Volltext

Verfügbarkeit prüfen

A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma

Clinical lung cancer, 2003-03, Vol.4 (5), p.294-297

2003

Link zum Volltext

Verfügbarkeit prüfen

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer

Lung cancer (Auckland), 2017-01, Vol.8, p.217-229

2017

Link zum Volltext

Verfügbarkeit prüfen

Peptide receptor radionuclide therapy of Merkel cell carcinoma using 177lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology

Annals of nuclear medicine, 2012-05, Vol.26 (4), p.365-369

2012

Link zum Volltext

Verfügbarkeit prüfen

Severe non-haematological toxicity after treatment with gemcitabine

Journal of cancer research and clinical oncology, 1999-11, Vol.125 (11), p.637-640

1999

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Multicenter, Open-Label Phase II Study of Gemcitabine plus Single-Dose Versus Split-Dose Carboplatin in the Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer

Clinical lung cancer, 2006-09, Vol.8 (2), p.135-139

2006

Link zum Volltext

Verfügbarkeit prüfen

65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8013-8013

2013

Link zum Volltext

Verfügbarkeit prüfen

CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS8117-TPS8117

2013

Link zum Volltext

Verfügbarkeit prüfen

Peptide receptor radionuclide therapy of Merkel cell carcinoma using ^sup 177^lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology

Annals of nuclear medicine, 2012-05, Vol.26 (4), p.365

2012

Link zum Volltext

Verfügbarkeit prüfen

Peptide receptor radionuclide therapy of Merkel cell carcinoma using super(177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology

Annals of nuclear medicine, 2012-05, Vol.26 (4), p.365-369

2012

Link zum Volltext

Verfügbarkeit prüfen

PD4-2-3: Global Lung Oncology Branch trial 3 (Glob 3): final results of a randomised multinational Phase III study of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S451-S451

2007

Link zum Volltext

Verfügbarkeit prüfen

Behavior of circulating epithelial tumor cells (CETC) and FISH (fluorescence in situ hybridisation) of epidermal growth factor receptor (EGFR)-gene amplification in lung cancer patients during the course of therapy

Advances in lung cancer, 2013, Vol.2 (1), p.1-8

2013

Link zum Volltext

Verfügbarkeit prüfen

Eighth World Conference on Lung Cancer

Journal of cancer research and clinical oncology, 1998-02, Vol.124 (1), p.62-64

Schneider, Claus-Peter

1998

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 135

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(132)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(32)
Life Sciences & Biomedicine
(28)
Humans
(23)
Oncology
(19)
Middle Aged
(16)
Male
(15)
Female
(14)
Aged
(13)
Banking Law
(12)
Adult
(11)
Lung Cancer
(11)
Lung Neoplasms - Pathology
(11)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(10)
Lung Neoplasms - Drug Therapy
(10)
Aged, 80 And Over
(8)
Carcinoma, Non-Small-Cell Lung - Pathology
(7)
Chemotherapy
(7)
Respiratory System
(7)
Treatment Outcome
(7)
Tumors
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

CRR visuell: Die neuen EU-Vorschriften der Capital Requirements Regulation

ZAG: Kommentar zum Zahlungsdiensteaufsichtsgesetz

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer

Experience With Afatinib in Patients With Non‐Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib

Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology

Randomized Phase II Study of Ixabepilone or Paclitaxel Plus Carboplatin in Patients With Non–Small-Cell Lung Cancer Prospectively Stratified by Beta-3 Tubulin Status

Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)

Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study

Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study

Standardized quantification of circulating peripheral tumor cells from lung and breast cancer

A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Peptide receptor radionuclide therapy of Merkel cell carcinoma using 177lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology

Severe non-haematological toxicity after treatment with gemcitabine

Randomized, Multicenter, Open-Label Phase II Study of Gemcitabine plus Single-Dose Versus Split-Dose Carboplatin in the Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer

65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC)

CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology

Peptide receptor radionuclide therapy of Merkel cell carcinoma using ^sup 177^lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology

Peptide receptor radionuclide therapy of Merkel cell carcinoma using super(177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology

PD4-2-3: Global Lung Oncology Branch trial 3 (Glob 3): final results of a randomised multinational Phase III study of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC)

Behavior of circulating epithelial tumor cells (CETC) and FISH (fluorescence in situ hybridisation) of epidermal growth factor receptor (EGFR)-gene amplification in lung cancer patients during the course of therapy

Eighth World Conference on Lung Cancer

Suchergebnisse filtern